Home / Research Library / Efficacy and safety of a novel dual GIP and GLP-1...
🧬 Medicine & Biology OpenAlex

Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial

📅 June 27, 2021 👤 Julio Rosenstock, Carol Wysham, Juan P. Frías et al. 📖 The Lancet 📊 991 citations

🤖 Plain-English Summary

This research explores Efficacy and safety of a novel dual GIP and GLP-1 receptor a..., contributing new insights to the field of Medicine & Biology.

🔑 Key Findings

  • Research demonstrates significant advances in patient outcome data
  • Study provides new evidence regarding clinical efficacy results
  • Findings open new directions for biological mechanism insights

💡 Why This Matters

Understanding this could lead to better treatments, improved diagnostics, or a deeper grasp of how the human body works — benefiting patient care globally.

Read the full paper
Access the original peer-reviewed research via OpenAlex.

View on DOI ↗

📋 Article Details

Category 🧬 Medicine & Biology
Published Jun 27, 2021
Journal The Lancet
Authors Julio Rosenstock, Carol Wysham, Juan P. Frías, Shizuka Kaneko, Clare J. Lee
DOI 10.1016/s0140-6736(21)01324-6
Citations 991
Source OpenAlex

More 🧬 Medicine & Biology Research